Blog
Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.
Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
Replacing Animal Models with Human-Relevant New...
Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
Immunogenicity Risk Assessment Outputs to Drive...
Advancing Immunogenicity Science: EpiVax in 2025
In 2025, EpiVax advanced the science of...
EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
EpiVax Supports Life-Saving Programs Through...
Doing Well and Giving Back in December
Doing Well and Giving Back in December On Being...
The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation
The Power of Tregs: From Sakaguchi’s Nobel...
The Tregs as Medicine Symposium | Advances in Tolerance Research
The Tregs as Medicine Symposium September 26,...
Optimize Your Immunogenicity Strategy with Trusted Expert Advice
Optimize Your Immunogenicity Strategy with...
Tregs, Epitopes, and the Future of Immune Tolerance
Tregs, Epitopes, and the Future of Immune...
The Platinum Vaccine & Change is Good!
The new CSO starts on June 1st! Drumroll...
Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
FDA Roadmap to Reducing Animal Testing: A Step...
Is “Artificial” Intelligence an Option for your ADA ?
Is "Artificial" Intelligence an Option for your...